Clinical Trial Update: A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Enicepatide (CT-388) is being studied in a Phase 2 trial for adults who are overweight or obese with Type 2 Diabetes Mellitus, and the study is currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Enicepatide (CT-388) (Enicepatide)

Snippet

Sponsor: Carmot Therapeutics, Inc. | Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Status: ACTIVE_NOT_RECRUITING